Advanced search
1 file | 758.30 KB Add to list

Ten years single-centre experience with intra-aortic balloon pump

GUY VANDENPLAS (UGent) , Thierry Bové (UGent) , Frank Caes (UGent) , Yves Van Belleghem (UGent) , Katrien Francois (UGent) , Filip De Somer (UGent) , Yvo Taeymans (UGent) and Guido Van Nooten (UGent)
(2011) ACTA CARDIOLOGICA. 66(6). p.707-713
Author
Organization
Abstract
Objectives The objective of this study was to investigate the patient characteristics and outcomes in 1406 patients undergoing intra-aortic balloon pump (IABP) counterpulsation. Methods Between 1998 and 2008, 1406 consecutive patients were recorded in a prospective database. Based on the main clinical indication for IABP use, we defined 3 groups: group A, 630 cases of coronary ischaemia or infarction without serious left ventricular (LV) dysfunction; group B, 466 patients with left ventricular failure or cardiogenic shock; group C, 310 patients where IABP was used for miscellaneous procedures such as weaning from cardiopulmonary bypass or during high-risk angioplasty or surgery. Results Global mortality was 28% (n = 390), with a significant difference between group A (15%, n=95) and group B (41%, n = 191) (P < 0.001). Mortality in group C was 34% (n = 104). Most insertions were done in the catheterization laboratory (n = 943) with subsequent mortality of 23% whereas 199 balloons were inserted in the operation room with 34% mortality. 170 balloons inserted in the intensive care unit resulted in 46% mortality (P <0.001). Major IABP-induced complications were 6.8% with no statistical differences between the three groups. Advanced age, left ventricular failure and low BMI were identified as prognostic risk factors for early mortality. Conclusions IABP deployed at an early clinical stage yields the best results, especially for acute coronary patients with preserved LV function whereas LV failure and late insertion result in worse outcome.
Keywords
IABP, THERAPY, Intra-aortic balloon pump, cardiogenic shock, IMPROVES, left ventricular failure, SURGERY, COUNTERPULSATION, REGISTRY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 758.30 KB

Citation

Please use this url to cite or link to this publication:

MLA
VANDENPLAS, GUY, Thierry Bové, Frank Caes, et al. “Ten Years Single-centre Experience with Intra-aortic Balloon Pump.” ACTA CARDIOLOGICA 66.6 (2011): 707–713. Print.
APA
VANDENPLAS, G., Bové, T., Caes, F., Van Belleghem, Y., Francois, K., De Somer, F., Taeymans, Y., et al. (2011). Ten years single-centre experience with intra-aortic balloon pump. ACTA CARDIOLOGICA, 66(6), 707–713.
Chicago author-date
VANDENPLAS, GUY, Thierry Bové, Frank Caes, Yves Van Belleghem, Katrien Francois, Filip De Somer, Yvo Taeymans, and Guido Van Nooten. 2011. “Ten Years Single-centre Experience with Intra-aortic Balloon Pump.” Acta Cardiologica 66 (6): 707–713.
Chicago author-date (all authors)
VANDENPLAS, GUY, Thierry Bové, Frank Caes, Yves Van Belleghem, Katrien Francois, Filip De Somer, Yvo Taeymans, and Guido Van Nooten. 2011. “Ten Years Single-centre Experience with Intra-aortic Balloon Pump.” Acta Cardiologica 66 (6): 707–713.
Vancouver
1.
VANDENPLAS G, Bové T, Caes F, Van Belleghem Y, Francois K, De Somer F, et al. Ten years single-centre experience with intra-aortic balloon pump. ACTA CARDIOLOGICA. 2011;66(6):707–13.
IEEE
[1]
G. VANDENPLAS et al., “Ten years single-centre experience with intra-aortic balloon pump,” ACTA CARDIOLOGICA, vol. 66, no. 6, pp. 707–713, 2011.
@article{2131350,
  abstract     = {Objectives The objective of this study was to investigate the patient characteristics and outcomes in 1406 patients undergoing intra-aortic balloon pump (IABP) counterpulsation. 
Methods Between 1998 and 2008, 1406 consecutive patients were recorded in a prospective database. Based on the main clinical indication for IABP use, we defined 3 groups: group A, 630 cases of coronary ischaemia or infarction without serious left ventricular (LV) dysfunction; group B, 466 patients with left ventricular failure or cardiogenic shock; group C, 310 patients where IABP was used for miscellaneous procedures such as weaning from cardiopulmonary bypass or during high-risk angioplasty or surgery. 
Results Global mortality was 28% (n = 390), with a significant difference between group A (15%, n=95) and group B (41%, n = 191) (P < 0.001). Mortality in group C was 34% (n = 104). Most insertions were done in the catheterization laboratory (n = 943) with subsequent mortality of 23% whereas 199 balloons were inserted in the operation room with 34% mortality. 170 balloons inserted in the intensive care unit resulted in 46% mortality (P <0.001). Major IABP-induced complications were 6.8% with no statistical differences between the three groups. Advanced age, left ventricular failure and low BMI were identified as prognostic risk factors for early mortality. 
Conclusions IABP deployed at an early clinical stage yields the best results, especially for acute coronary patients with preserved LV function whereas LV failure and late insertion result in worse outcome.},
  author       = {VANDENPLAS, GUY and Bové, Thierry and Caes, Frank and Van Belleghem, Yves and Francois, Katrien and De Somer, Filip and Taeymans, Yvo and Van Nooten, Guido},
  issn         = {0001-5385},
  journal      = {ACTA CARDIOLOGICA},
  keywords     = {IABP,THERAPY,Intra-aortic balloon pump,cardiogenic shock,IMPROVES,left ventricular failure,SURGERY,COUNTERPULSATION,REGISTRY},
  language     = {eng},
  number       = {6},
  pages        = {707--713},
  title        = {Ten years single-centre experience with intra-aortic balloon pump},
  url          = {http://dx.doi.org/10.2143/AC.66.6.2136953},
  volume       = {66},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: